Item 9A. Controls and Procedures
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive and financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control — Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2021. Pursuant to Section 404(c) of the Sarbanes-Oxley Act, our independent registered public accounting firm has issued an attestation report on the effectiveness of our internal control over financial reporting for the year ended December 31, 2021, which is included below.
Management's Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term as defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive and financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.
As the acquisition of BioDiscovery occurred in the fourth quarter of 2021, we excluded the internal control over financial reporting of BioDiscovery from the scope of our assessment of the effectiveness of the Company’s internal controls. This exclusion is in accordance with the general guidance issued by the Staff of the SEC that an assessment of a recently-acquired business may be omitted from our scope in the year of acquisition, if specified conditions are satisfied. Goodwill and net intangibles assets acquired were not excluded from our assessment. BioDiscovery's total net assets excluded from our assessment constituted approximately 3% of the Company’s total assets as of December 31, 2021, and BioDiscovery revenues excluded from our assessment represented approximately 6% of the Company’s total revenue for the year ended December 31, 2021.
Remediation of Previously Disclosed Material Weakness
As disclosed in Item 9A in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 23, 2021, our management previously identified material weaknesses in our internal control environment over financial reporting related to an insufficient number of resources to support the growth and complexity of our financial reporting requirements. Specifically, the design of certain controls did not adequately provide appropriate segregation of duties. The failure to maintain appropriate segregation of duties had a pervasive impact and as such, this deficiency resulted in a risk that could have impacted all financial statement account balances and disclosures. The material weaknesses did not result in any identified material misstatements to our financial statements, and there were no changes to previously released financial results. During 2021, our management, with the oversight of the Audit Committee of our Board of Directors, engaged in efforts to remediate the material weaknesses identified and previously disclosed. We completed these remediation measures in the quarter ended December 31, 2021, including testing of the design and concluding on the operating effectiveness of the related controls.
Specifically, remediation efforts that we implemented during 2021 include the following:
• Management engaged external consultants to assist with our internal accounting functions and further enhance our internal controls, which increased the number of external personnel involved in financial reporting.
106
Table of Contents
• We hired a new Chief Financial Officer, a Senior Manager SEC Reporting & Technical Accounting, a Senior Manager of Accounting, and a Senior Accountant, which has increased the number of qualified full-time employees involved in our financial reporting and the control environment.
Accordingly, we have determined that the material weaknesses are considered to be remediated. The financial statements and internal control over financial reporting have been audited by BDO USA LLP, an independent registered public accounting firm. BDO’s reports with respect to fairness of the presentation of the financial statements, and the effectiveness of internal control over financial reporting, are included herein.
Changes in Internal Control over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15-d-15(f) under the Exchange Act) that occurred during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Report of Independent Registered Public Accounting Firm
Stockholders and Board of Directors
Bionano Genomics, Inc.
San Diego, CA
Opinion on Internal Control over Financial Reporting
We have audited Bionano Genomic, Inc’s. (the “Company’s”) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended, and the related notes and our report dated March 1, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
As indicated in the accompanying Item 9A, Management’s Annual Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of BioDiscovery, LLC., which was acquired during the fourth quarter of 2021, and which is included in the consolidated balance sheet of the Company as of December 31, 2021, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the year then ended. BioDiscovery, LLC. constituted approximately 3% of the Company’s total assets as of December 31, 2021 and approximately 6% of revenues for the year then ended. Management did not assess the effectiveness of internal control over financial reporting of BioDiscovery, LLC. because of the timing of the acquisition. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of BioDiscovery, LLC.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
107
Table of Contents
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ BDO USA, LLP
San Diego, CA
March 1, 2022
ITEM 9B. OTHER INFORMATION
None.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE
The information required by this item will be set forth under the captions “Election of Directors,” “Delinquent Section 16(a) Reports,” “Information Regarding the Board of Directors and Corporate Governance,” in our definitive proxy statement to be filed with the Securities and Exchange Commission in connection with our 2022 Annual Meeting of Stockholders, or the Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2021, and is incorporated in this Annual Report by reference.
We have adopted a code of business conduct and ethics, or the Ethics Code, that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of the Ethics Code is available on our website at www.bionanogenomics.com. If we make any substantive amendments to the Ethics Code or grant any waiver from a provision of the Ethics Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K. Information contained in, or that can be accessed through, our website is not incorporated by reference herein, and you should not consider information on our website to be part of this Annual Report.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item will be set forth under the caption “Executive and Director Compensation” in the Proxy Statement and is incorporated in this Annual Report by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this item will be set forth under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” in the Proxy Statement and is incorporated in this Annual Report by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this item will be set forth under the captions “Transaction With Related Persons and Indemnification” and “Information Regarding the Board of Directors and Corporate Governance” in the Proxy Statement and is incorporated in this Annual Report by reference.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this item will be set forth under the caption “Principal Accountant Fees and Services” in the Proxy Statement and is incorporated in this Annual Report by reference.
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a) List the following documents filed as a part of the report:
108
Table of Contents
(1) Financial statements
The response to this portion of Item 15 is set forth under Item 8 above.
The following consolidated financial statements of Bionano Genomics, Inc are included in Item 8 of this report:
◦ Reports of Independent Registered Public Accounting Firm
◦ Consolidated Balance Sheets — December 31, 2021 and 2020
◦ Consolidated Statements of Operations — Years ended December 31, 2021 and 2020
◦ Consolidated Statements of Comprehensive Income — Years ended December 31, 2021 and 2020
◦ Consolidated Statements of Cash Flows — Years ended December 31, 2021 and 2020
◦ Notes to Consolidated Financial Statements
(2) Financial statement schedule.
All schedules have been omitted because they are not required or because the required information is given in the financial statements or notes thereto set forth under Item 8 above.
(3) Exhibits
A list of exhibits file with this Annual Report or incorporated herein by reference can be found in the Exhibit Index below.
Exhibit Index
Exhibit
Number Description
2.1^ (1)
Agreement and Plan of Merger, dated August 21, 2020, by and among the Company, Alta Merger Sub, Inc., Lineagen, Inc. and Michael S. Paul, Ph.D.
2.2^€ (18)
Agreement and Plan of Merger, dated October 8, 2021, by and among the Company, Starship Merger Sub I, Inc., Starship Merger Sub II, LLC, BioDiscovery, Inc. and Soheil Shams.
3.1 (14)
Amended and Restated Certificate of Incorporation, as amended.
3.2 (2)
Amended and Restated Bylaws.
4.1 (3)
Form of Common Stock Certificate .
4.2 (3)
Form of Warrant to Purchase Series D-1 Preferred Stock issued to Midcap Financial Trust.
4.3 (3)
Form of Warrant to Purchase Common Stock Issued to Underwriters.
4.4 (3)
Form of Warrant Certificate (included in Exhibit 4.8).
4.5 (3)
Form of Warrant Agent Agreement by and between the Registrant and American Stock Transfer & Trust Company LLC, as warrant agent.
4.6 (4)
Form of Warrant to Purchase Common Stock for Service Providers.
4.7 (5)
Registration Rights Agreement, dated March 14, 2019, by and among the Company and the Innovatus Investors.
4.8 (6)
Form of Warrant to Purchase Common Stock issued to Investors in October 2019 Public Offering.
4.9 (13)
Form of Warrant to Purchase Common Stock issued to Investors in April 2020 Public Offering.
4.10 (15)
Underwriting Agreement, dated January 8, 2021, by and among Bionano Genomics, Inc. and Oppenheimer & Co. Inc., as representatives of the several underwriters named therein.
4.11 (16)
Underwriting Agreement, dated January 20, 2021, by and among Bionano Genomics, Inc. and Oppenheimer & Co. Inc., as representatives of the several underwriters named therein.
4.12 (14)
Description of the Company’s Securities.
10.1+ (3)
Bionano Genomics, Inc. Amended and Restated 2006 Equity Compensation Plan (the “2006 Plan”).
10.2+ (3)
Forms of grant notice, stock option agreement and notice of exercise under the 2006 Plan.
10.3+ (7)
Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended (the “2018 Plan”).
10.4+ (3)
Forms of grant notice, stock option agreement and notice of exercise under the 2018 Plan.
10.5+ (8)
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.
10.6+ (3)
Form of Indemnification Agreement by and between the Registrant and each director and executive officer.
10.7+ Bionano Genomics, Inc. Non-Employee Director Compensation Policy, as amended
109
Table of Contents
Exhibit
Number Description
10.8+ (3)
Employment Agreement by and between the Registrant and R. Erik Holmlin, Ph.D., dated November 7, 2017, as amended.
10.9+ (1)
Employment Agreement, effective as of September 1, 2020, by and between Christopher Stewart and the Company.
10.10+ (1)
Employment Agreement, effective as of August 31, 2020, by and between Alka Chaubey and the Company.
10.11+ (3)
Employment Agreement by and between the Registrant and Mark Oldakowski, dated November 7, 2017.
10.12 (3)
Lease by and between the Registrant and The Irvine Company LLC, dated January 16, 2012.
10.13 (3)
First Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated September 10, 2013.
10.14 (3)
Second Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated July 1, 2015.
10.15 (14)
Third Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated December 19, 2019.
10.16 (14)
Fourth Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated February 15, 2021.
10.17# (3)
Master Services Agreement by and between the Registrant and Skorpios Technologies, Inc. (f/k/a Novati Technologies, Inc. and f/k/a SVTC Technologies, LLC), dated March 2, 2009, as amended.
10.18# (3)
Manufacturing Services Agreement by and between the Registrant and Paramit Corporation, dated February 18, 2015.
10.19# (3)
License Agreement by and between Princeton University and the Registrant, dated January 7, 2004.
10.20# (3)
First Amendment to the License Agreement by and between Princeton University and the Registrant, dated December 17, 2004.
10.21# (3)
Second Amendment to the License Agreement by and between Princeton University and the Registrant, dated February 25, 2010.
10.22# (3)
Third Amendment to the License Agreement by and between Princeton University and the Registrant, dated October 17, 2011.
10.23# (3)
Fourth Amendment License Agreement by and between Princeton University and the Registrant, dated February 9, 2012.
10.24# (3)
License Agreement by and between the Registrant and Q Biotechnology CV dated May 1, 2014.
10.25# (3)
Amendment to Non-Exclusive Patent License Agreement by and between the Registrant and Q Biotechnology CV dated May 1, 2014.
10.26# (3)
License Agreement by and between the Registrant and New York University dated November 4, 2013.
10.27# (3)
Option and Sublicense Agreement by and between the Registrant and Pacific Biosciences of California, Inc. dated February 2, 2016.
10.28 (5)
Common Stock Purchase Agreement, dated March 14, 2019, by and among the Company and the Innovatus Investors.
10.29 (20)
Bionano Genomics, Inc. 2020 Inducement Plan, as amended.
10.30 (12)
Form of Stock Option Grant Notice and Stock Option Agreement under the Bionano Genomics, Inc. 2020 Inducement Plan.
10.31 (19)
Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Bionano Genomics, Inc. 2018 Equity Incentive Plan.
10.32 (17)
Sales Agreement, dated March 23, 2021, by and between the Company and Cowen and Company, LLC.
10.33
Standard Industrial/Commercial Single-Tenant Lease, made effective as of November 23, 2021, by and between the Company and 6777 Nancy Ridge LLC.
10.34^+
Employment Agreement , dated October 8, 2021 and effective October 18 , 2021, by and between the Company and Soheil Shams .
10.35+
Stock Restriction Agreement , dated O c tober 8, 2021 and effective October 18, 2021, by and between the Company and Soheil Sham s.
10.36+ Employment Agreement, dated June 14, 2021, by and between the Company and Richard Shippy
10.37 (5)
Common Stock Purchase Agreement, dated March 14, 2019, between the Company and Aspire Capital Fund, LLC
10.38 Commercial Single-Tenant Lease – Net, dated February 28, 2016, by and between Tesa Beach LLC and BioDiscovery, Inc.
10.39 Fifth Amendment to the Lease by and between the Registrant and The Irvine Company, LLC, dated January 12, 2022.
21.1 Subsidiaries of the Registrant.
23.1 Consent of BDO USA LLP, independent registered public accounting firm .
24.1 Power of Attorney (included on signature page).
31.1* Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
31.2* Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
110
Table of Contents
Exhibit
Number Description
32.1* Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2* Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
(1)
Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2020.
(2)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 24, 2018.
(3)
Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (File No. 333-225970), as amended.
(4)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on November 21, 2018.
(5)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 14, 2019.
(6)
Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (File No. 333-233828), as amended.
(7)
Incorporated by reference to the Registrant’s Registration Statement on Form S-8 (File No. 333-245764).
(8)
Incorporated by reference to the Registrant’s Registration Statement on Form S-8 (File No. 333-227073).
(9)
Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on August 8, 2019.
(10)
Incorporated by reference to the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 10, 2020.
(11)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 14, 2020.
(12)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 24, 2020.
(13)
Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (File No. 333-237074).
(14)
Incorporated by reference to the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 23, 2021.
(15)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 11, 2021.
(16)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 21, 2021.
(17)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 24, 2021.
(18)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 19, 2021.
(19)
Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on August 4, 2021.
(20)
Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 12, 2021.
^
Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.
+
Indicates management contract or compensatory plan.
#
Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.
€
Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by “[***]”) because the Company has determined that the information is not material and is the type that the Company treats as private or confidential.
*
This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
ITEM 16. FORM 10-K SUMMARY
None.
SIGNATURES
111
Table of Contents
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized .
Company Name
Date: March 1, 2022 By: /s/ R. Erik Holmlin, Ph.D.
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. , as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Bionano Genomics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
Signature Title Date
/s/ R. Erik Holmlin, Ph.D. Chief Executive Officer and Director
(Principal Executive Officer)
March 1, 2022
R. Erik Holmlin, Ph.D.
/s/ Christopher Stewart Chief Financial Officer
(Principal Financial and Accounting Officer)
March 1, 2022
Christopher Stewart
/s/ David L. Barker, Ph.D. Director March 1, 2022
David L. Barker, Ph.D.
/s/ Albert A. Luderer, Ph.D. Director March 1, 2022
Albert A. Luderer, Ph.D.
/s/ Yvonne Linney, Ph.D. Director March 1, 2022
Yvonne Linney, Ph.D.
/s/ Hannah Mamuszka Director March 1, 2022
Hannah Mamuszka
/s/ Aleksandar Rajkovic, M.D., Ph.D
Director March 1, 2022
Aleksandar Rajkovic, M.D., Ph.D.
/s/ Christopher Twomey Director March 1, 2022
Christopher Twomey
112
Table of Contents
/s/ Kristiina Vuori, M.D., Ph.D. Director March 1, 2022
Kristiina Vuori, M.D., Ph.D.
/s/ Vincent Wong, J.D., M.B.A. Director March 1, 2022
Vincent Wong, J.D., M.B.A.
113